|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:icosapent_ethyl
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:C10AX06
|
|
gptkbp:chemicalFormula
|
C22H34O2
|
|
gptkbp:clinicalTrialPhase
|
gptkb:REDUCE-IT
|
|
gptkbp:contraindication
|
hypersensitivity to icosapent ethyl
|
|
gptkbp:drugClass
|
omega-3 fatty acid derivative
|
|
gptkbp:form
|
capsule
2 g twice daily
|
|
gptkbp:genericName
|
gptkb:icosapent_ethyl
|
|
gptkbp:halfLife
|
89 hours
|
|
gptkbp:indication
|
reduce risk of cardiovascular events
reduce triglyceride levels
|
|
gptkbp:interactsWith
|
anticoagulants
antiplatelet drugs
|
|
gptkbp:legalStatus
|
Rx-only (US)
|
|
gptkbp:manufacturer
|
gptkb:Amarin_Corporation
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
increases triglyceride clearance
reduces hepatic VLDL-TG synthesis/secretion
|
|
gptkbp:patentExpired
|
2030 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:atrial_fibrillation
arthralgia
peripheral edema
|
|
gptkbp:usedFor
|
hypertriglyceridemia
cardiovascular risk reduction
|
|
gptkbp:bfsParent
|
gptkb:Amarin_Corporation
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
Vascepa
|